

Sun Min Lim

List of Publications by Citations

Source: <https://exaly.com/author-pdf/457783/sun-min-lim-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67

papers

1,362

citations

20

h-index

35

g-index

78

ext. papers

1,840

ext. citations

5.3

avg, IF

4.73

L-index

#	Paper	IF	Citations
67	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2613-2618	2.2	193
66	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. <i>International Journal of Cancer</i> , 2019 , 145, 1179-1188	7.5	110
65	A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 229-43	5.1	89
64	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. <i>Cancer Discovery</i> , 2020 , 10, 1194-1209	24.4	68
63	Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. <i>PLoS ONE</i> , 2014 , 9, e103333	3.7	61
62	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 643	4.9	57
61	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020 , 20, e10	6.1	51
60	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. <i>Lung Cancer</i> , 2014 , 83, 389-95	5.9	50
59	Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. <i>Yonsei Medical Journal</i> , 2012 , 53, 352-7	3	46
58	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016 , 7, 10547-56	3.3	44
57	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016 , 16, 385	4.8	37
56	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016 , 7, 36311-36320	3.3	36
55	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 740-763	8.9	36
54	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. <i>Lung Cancer</i> , 2014 , 83, 374-82	5.9	35
53	An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1588-95	7.5	32
52	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016 , 7, 24172-8	3.3	32
51	Association between Obesity Indices and Insulin Resistance among Healthy Korean Adolescents: The JS High School Study. <i>PLoS ONE</i> , 2015 , 10, e0125238	3.7	26

50	The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. <i>Gut and Liver</i> , 2013 , 7, 51-7	4.8	24
49	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362	10.1	23
48	Impact of cumulative time on the clinical outcomes of endoscopic submucosal dissection in gastric neoplasm. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013 , 27, 1397-403	5.2	21
47	Association between blood pressure and carotid intima-media thickness. <i>Journal of Pediatrics</i> , 2009 , 154, 667-71	3.6	19
46	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. <i>Future Oncology</i> , 2013 , 9, 377-86	3.6	17
45	Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 491-500	8.9	17
44	Psychosocial impact of cancer patients on their family members. <i>Cancer Research and Treatment</i> , 2013 , 45, 226-33	5.2	15
43	Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2042-50	5.6	15
42	Rare Incidence of Rearrangement in Cholangiocarcinoma. <i>Cancer Research and Treatment</i> , 2017 , 49, 185-192	4.2	15
41	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2238-48	6.1	14
40	Fever-induced QTc prolongation and ventricular fibrillation in a healthy young man. <i>Yonsei Medical Journal</i> , 2011 , 52, 1025-7	3	14
39	Immune adjuvant effect of a <i>Toxoplasma gondii</i> profilin-like protein in autologous whole-tumor-cell vaccination in mice. <i>Oncotarget</i> , 2016 , 7, 74107-74119	3.3	13
38	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , 2016 , 93, 1-8	5.9	11
37	Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019 , 60, 898-904	3	11
36	Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2013 , 80, 313-8	5.9	10
35	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016 , 30, 279-86	2.5	9
34	Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. <i>PLoS ONE</i> , 2016 , 11, e0154133	3.7	9
33	The promise of bispecific antibodies: Clinical applications and challenges. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102240	14.4	9

32	A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 539-48	3.5	8
31	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 2015 , 47, 9-17	5.2	7
30	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in -positive non-small-cell lung cancer 2020 , 8,		7
29	AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. <i>Lung Cancer</i> , 2020 , 146, 70-77	5.9	6
28	Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. <i>Lung Cancer</i> , 2017 , 111, 79-83	5.9	5
27	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2015 , 10, e0137678	3.7	5
26	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4397-4409	12.9	5
25	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. <i>Lung Cancer</i> , 2016 , 95, 57-64	5.9	5
24	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 153, 179-189	7.5	5
23	Prognostic Value of mRNA Expression in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	4
22	Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020 , 52, 1112-1119	5.2	4
21	A case of synchronous squamous cell carcinoma in the esophagus and stomach. <i>Gut and Liver</i> , 2012 , 6, 118-21	4.8	4
20	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1627-36	6.1	4
19	Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021 , 12, 598671	8.4	4
18	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	3
17	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.. <i>Frontiers in Oncology</i> , 2022 , 12, 811247	5.3	3
16	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd- generation EGFR-TKI, in EGFR-mutant NSCLC 2021 ,		2
15	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021 , 10, 7012-7020	4.8	2

14	Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients. <i>Oncology</i> , 2015 , 88, 195-200	3.6	1
13	Predicting treatment outcomes using F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211068732	5.4	1
12	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.. <i>Yonsei Medical Journal</i> , 2022 , 63, 42-55	3	1
11	Genomic landscape of extraordinary responses in metastatic breast cancer. <i>Communications Biology</i> , 2021 , 4, 449	6.7	1
10	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. <i>Cancers</i> , 2021 , 13,	6.6	1
9	Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.. <i>Cancer Discovery</i> , 2022 , 12, 16-19	4.4	0
8	Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.. <i>Cancer Research</i> , 2022 , 82, 18-20	10.1	0
7	Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100180	1.4	0
6	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2741-2750	4.9	0
5	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
4	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079125	5.4	0
3	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.. <i>Frontiers in Oncology</i> , 2022 , 12, 821391	5.3	0
2	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.. <i>Current Oncology</i> , 2022 , 29, 2154-2164	2.8	0
1	Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2012 , 34, 309-16		